Metformin and Colorectal Cancer.
Metformin and Colorectal Cancer.
复制标题
DOI：
10.3389/fendo.2018.00622
复制
发表时间：
2018
影响因子：
5.2
通讯作者：
Nakajima A
中科院分区：
文献类型：
--
作者：
Higurashi T;Nakajima A
结直肠癌是人类最常见的肿瘤之一。CRC的发病率一直在增加，需要新的预防策略，包括化学预防，以降低其发病率和相关死亡率。二甲双胍是一种常用于治疗糖尿病的双胍化合物。最近的许多基础研究、流行病学和临床试验研究表明，二甲双胍不仅在糖尿病治疗中有益处，而且在降低癌症（包括CRC）发生风险方面也有益处。这些研究表明，二甲双胍可能是CRC的候选化学预防剂。这篇综述文章将讨论二甲双胍治疗和CRC的现有证据，以及概述我们在研究二甲双胍用于结直肠肿瘤化学预防治疗中的挑战。
Colorectal Cancer (CRC) is one of the most frequently encountered neoplasms in humans. The incidence of CRC has been increasing and new strategies for prevention, including chemoprevention, are required to lower its incidence and associated mortality. Metformin is a biguanide compound commonly used for the treatment of diabetes mellitus. Many recent basic research, epidemiological and clinical trial studies have indicated that metformin has benefits not only in diabetes treatment, but also in lowering the risk of developing cancer (including CRC). These studies indicate that metformin may be a candidate chemoprevention agent for CRC. This review article shall discuss the present evidence of metformin treatment and CRC, as well as outline our challenge in the investigation of metformin use in chemoprevention therapy for colorectal tumors.